Enveric Biosciences on Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward

Enveric Biosciences (NASDAQ: ENVB) is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients, and initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy, according to the company’s website (see here: www.enveric.com). SNNLive spoke with David Johnson, Chairman and CEO of Enveric Biosciences via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

- 0:28​​ Recent news on March 10, 2021: Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

- 2:01 History of Enveric Biosciences - how the company got to where it is at today

- 3:17 What makes the company unique and different compared to its peers

- 5:09 Closest comparison to Enveric Biosciences

- 6:54 David Johnson's background

- 8:13 Value catalysts moving forward

For more information about Enveric Biosciences, please visit: www.enveric.com

The interview may contain forward looking statements about Enveric Biosciences. See Enveric Biosciences' periodic filings with Securities and Exchange Commission for more complete information.

Please read our full disclosure here.